Salute e Benessere

XYRA Announces the Issuance of a Fifth New US Patent in a Series of Patents…

The fifth patent, (Patent No. 11,975,202) covers the use of budiodarone and monitoring with wearables to prevent progression of non-permanent to permanent AF. Progression of non-permanent to permanent AF occurs frequently and is associated with high risk of thrombo-embolic strokes, heart attacks, congestive heart failure and poor outcomes. Preventing such progression would have immense public health benefits for the up to 7 million US subjects with non-permanent AF who are destined to progress…
PR Newswire
24/04/2025

Sun Pharma and Moebius Medical Announce Dual Publications on MM-II's Phase 2b…

- MM-II recently granted Fast Track Designation by the US FDA - - MM-II recently granted Fast Track Designation by the US FDA - MUMBAI, IndiaandTEL AVIV, Israel , April 24, 2025 /PRNewswire/ -- Sun Pharma (Reuters: SUN.BO) (Bloomberg: SUNP IN) (NSE: SUNPHARMA) (BSE: 524715 ) (Sun Pharmaceutical Industries Limited, and includes its subsidiaries or associate companies)andIsrael -based Moebius Medical Limited announced today the publication of two articles inOsteoarthritis...
PR Newswire
24/04/2025

Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial…

Peter Nicklin, Chairman of the Board, Hansa Biopharma said, "In Q1, the Company delivered strong growth with total revenue of 66.3 MSEK and products sales of 65.7 MSEK. This represents a 39 percent increase as compared to Q1 2024 (47.4 MSEK). While the organ allocation market remains unpredictable and directly impacts our quarterly sales, we remain confident in our ability to significantly increase revenue year on year. In Q1, we completed enrollment in the Post Authorization Efficacy and…
PR Newswire
24/04/2025

Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates…

Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment optionsPatients treated with elafibranor versus placebo showed significant improvements in liver biochemical parameters, including alkaline phosphatase (ALP)Stabilization of non-invasive markers of liver fibrosis were observed in patients on elafibranor versus placeboA significant improvement...
Nasdaq GlobeNewswire
24/04/2025

Pharming Group to report first quarter 2025 financial results on May 8

Leiden, the Netherlands, April 24, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2025 financial results, for the period ended March 31, on Thursday, May 8, 2025. Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on May 8, 2025. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information...
Nasdaq GlobeNewswire
24/04/2025

Sustainable Period Care in Australia: Why Women Are Switching to Menstrual Discs…

Recognised for its innovation and impact, my mimi was recently awarded Best Sustainable Period Care Solution in Australia of 2025, affirming its place at the forefront of eco-conscious wellness. Recognised for its innovation and impact, my mimi was recently awardedBest Sustainable Period Care Solution inAustraliaof 2025, affirming its place at the forefront of eco-conscious wellness. Designed for up to 12 hours of wear - even on heavy flow days - the my mimi disc provides discreet,...
PR Newswire
24/04/2025

Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed

Sanofi: strong Q1 performance and 2025 guidance confirmedParis, April 24, 2025Q1 sales growth of 9.7% at CER 1and business EPS 2of €1.79Pharma launches reached sales of €0.8 billion, up 43.8%, driven by ALTUVIIIODupixent sales were €3.5 billion, up 20.3%Vaccines sales were €1.3 billion, up 11.4%, driven by favorable Beyfortus phasingResearch and Development expenses reached €1.8 billion, up 6.9%Selling, general and administrative expenses were €2.2 billion, up...
Nasdaq GlobeNewswire
24/04/2025

ONWARD Medical Establishes US ADR Program and Begins Trading on OTCQX Best…

Sponsored Level 1 ADR program facilitates trading by US investors following recent FDA clearance and commercial launchBNY will be ADR depositary bankTicker symbol for US investors isONWRYEINDHOVEN, the Netherlands, April24, 2025(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and OTCQX:ONWRY ), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI)...
Nasdaq GlobeNewswire
24/04/2025

Interim Report Quarter 1, 2025: Essity

Quarter 1, 2025 Quarter 1, 2025 CEO'S COMMENTS Essity began the year with positive organic sales growth in all business areas, stable profitability and continued strong cash flow. In these turbulent times, Essity's strength becomes clear – with production close to our customers and consumers, we deliver leading hygiene and health solutions that are needed every day. Higher sales and a strong product portfolio All business areas reported positive organic sales growth for the...
PR Newswire
24/04/2025

Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone…

Allschwil, Switzerland, April 24, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that the sales of the antifungal Cresemba ®(isavuconazole) in Japan exceeded the threshold triggering a sales milestone payment from its partner Asahi Kasei Pharma (AKP), amounting to approximately CHF 1.7 million. This is the second milestone payment from...
Nasdaq GlobeNewswire
24/04/2025

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into…

Group salesgrew by 6% 1at constant exchange rates (CER; 7% in CHF), driven by high demand for newer medicines and diagnostic solutions. Pharmaceuticals Division salesrose by 8% (9% in CHF) on continued strong demand for a broad range of our medicines; top growth drivers were Phesgo (breast cancer), Vabysmo (severe eye diseases), Xolair (allergies) and Hemlibra (haemophilia A). Diagnostics Division salesremained stable with high demand across products and regions offsetting the...
Nasdaq GlobeNewswire
24/04/2025

Addex Therapeutics to Release Full-Year 2024 Financial Results and Host…

Geneva, Switzerland, April 24, 2025-Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Full-Year 2024 Financial Results on April 25, 2025. Tim Dyer, CEO, and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and...
Nasdaq GlobeNewswire
24/04/2025

Metastatic Colorectal Cancer Market Poised for Expansion Across the 7MM During…

Seen in approximately 45% CRC patients, KRAS mutations significantly influence the prognosis and treatment outcomes. These mutations are associated with a more aggressive disease course, resistance to chemotherapy and targeted therapies, and overall poorer survival rates. Seen in approximately45%CRC patients, KRAS mutations significantly influence the prognosis and treatment outcomes. These mutations are associated with a more aggressive disease course, resistance to chemotherapy and...
PR Newswire
23/04/2025

Galapagos Reports First Quarter 2025 Financial Results, Recent Business…

First U.S. patient dosed in ATALANTA-1 study of GLPG5101Mantle cell lymphoma (MCL), a high-unmet-need hematological malignancy, selected as lead indication for the GLPG5101 program; Pivotal development planned to start in 2026 and aiming for approval in 2028Executive leadership changes with Dr. Paul Stoffels retiring as CEO upon appointment of his successor while continuing as Chair of the Board, Thad Huston departing as CFO/COO on August 1, 2025, and Henry Gosebruch appointed...
Nasdaq GlobeNewswire
23/04/2025

AB Science announces that EMA granted orphan drug status to AB8939 for the…

PRESS RELEASEEUROPEAN MEDICINES AGENCY (EMA) HAS GRANTED ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIAParis, April 23, 2025, 6.45pm CETAB Science SA(Euronext - FR0010557264 - AB) announces today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia (AML).AB8939 had already obtained orphan drug designation from...
Nasdaq GlobeNewswire
23/04/2025

EssilorLuxottica: Q1 2025 Revenue - Strong revenue growth in the first quarter

Strong revenue growth in the first quarterGroup's revenue up 8.1% at current and 7.3% at constant exchange rates 1in Q1Sound growth in both PS and DTC channels, with comparable-store sales 3up 8%EMEA growing 10% at constant exchange rates 1, equally boosted by the two channelsNA growing 4%, with solid trends in DTC and resilient demand in PSAsia-Pacific up double digits, with myopia solutions strong in ChinaRay-Ban Meta growing fast, with high...
Nasdaq GlobeNewswire
23/04/2025

OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO…

OSE Immunotherapeutics Highlights Abstracts Selected forPresentation at ASCO 2025Featuring proprietary asset Tedopi® and two partnered SIRPα inhibitor assets with Boehringer IngelheimNANTES, France – April 23, 2025, 6:00 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that several abstracts highlighting the Company's innovative...
Nasdaq GlobeNewswire
23/04/2025

Essity decides on new share buyback program of SEK 3bn

The share buyback program will be managed by BofA Securities Europe SA, which will decide on the date for repurchasing independently from and outside of Essity's influence. Repurchasing will take place on Nasdaq Stockholm in accordance with the stock exchange's issuer regulations and be implemented in accordance with the EU Market Abuse Regulation (MAR) and the European Commission's Delegated Regulation 2016/1052 (Safe Harbour Regulation). The share buyback program will be managed by BofA...
PR Newswire
23/04/2025

Latin America Advanced Wound Care Market worth US$498.2 million by 2030 with…

Browse in-depth TOC on 'Latin America Advanced Wound Care Market'186 - Tables47 - Figures221 - Pages Browse in-depth TOC on 'Latin America Advanced Wound Care Market' 186 - Tables 47 - Figures 221 - Pages By Based on wound type,the LATAM advanced wound care market is segmented into acute wounds and chronic wounds. The chronic wounds segment accounted for the largest share of the market in 2024. The large share of this segment can be attributed to the rising number of traffic...
PR Newswire
23/04/2025

FLEX Vessel Prep™ System FLEX FIRST AV Registry 6-Month Data and the Hamburg…

Ari Kramer, MDPrimary InvestigatorSpartanburg Medical CenterSpartanburg, South Carolina Ari Kramer, MD Primary Investigator Spartanburg Medical CenterSpartanburg, South Carolina "The FLEX VP System has changed the way I approach resistant stenoses. This study confirms what I've seen firsthand—controlled-depth micro-incisions offer not only technical precision but also real clinical impact in reducing reinterventions. This is not just about another tool. FLEX represents a paradigm shift...
PR Newswire
23/04/2025

Global Nutraceuticals Market to Grow by USD 668 Billion by 20233, Driven by…

The COVID-19 pandemic marked a turning point, accelerating consumer interest in immunity-boosting supplements. Products containing vitamin C, D, zinc, and other immune-supporting ingredients saw record sales. Leading brands like GNC, Herbalife, and Nature's Bounty responded swiftly with expanded product lines. Beyond immune health, the market has seen increased demand for stress relief, gut health, and energy-enhancing supplements. This sustained shift toward proactive health has cemented…
PR Newswire
23/04/2025

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell…

Houston, Texas and Tuebingen, Germany, April 23, 2025 –Immatics N.V.(NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced upcoming presentations on its lead cell therapy product candidate, IMA203 TCR T-cell therapy targeting PRAME, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 30 – June 3, 2025, in Chicago,...
Nasdaq GlobeNewswire
23/04/2025

Call for Nominations: Seventh Annual .ORG Impact Awards to Recognize Global…

RESTON, Va., April 23, 2025 /PRNewswire/ -- Public Interest Registry (PIR), the nonprofit stewards of the .ORG domain, today opened the nomination period for its seventh annual .ORG Impact Awards, an annual celebration that recognizes outstanding mission-driven individuals and organizations from the global .ORG Community for their positive contributions to society. RESTON, Va. , April 23, 2025 /PRNewswire/ -- Public Interest Registry (PIR), the nonprofit stewards of the.ORG domain,...
PR Newswire
23/04/2025

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), PRESENTING…

The May issue of CRST will contain results from a Patient Experience survey conducted with first time and repeat LACRIFILL Canalicular Gel patients of MDs and ODs, where 98.11% of respondents answered "yes" when asked if they will come back in the future for another dose of LACRIFILL Canalicular Gel. The May issue ofCRSTwill contain results from a Patient Experience survey conducted with first time and repeat LACRIFILL Canalicular Gel patients of MDs and ODs, where 98.11% of…
PR Newswire
23/04/2025
Altri  Comunicati